logo
Plus   Neg
Share
Email

Altimmune Begins Phase 2 Clinical Trial Of HepTcell - Quick Facts

Altimmune, Inc. (ALT) has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a peptide-based immunotherapeutic under development for treatment of chronic hepatitis B. The study is being conducted in the United States, Canada and Europe and is a double-blind, randomized, placebo-controlled study of 80 adult patients. The primary efficacy endpoint is virological response.

"Based on the encouraging preclinical and clinical data we are optimistic that HepTcell may be ideal in combination with novel direct-acting antivirals to achieve a functional cure for this disease," said Scott Harris, Chief Medical Officer of Altimmune.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Australian government has passed the newly amended Media Bargaining Code in the parliament which requires technology giants Facebook and Google to pay for local Australian news content that is shared on their platforms. Regeneron Pharmaceuticals, Inc. (REGN) Thursday said it stopped enrollment into the placebo group for its Phase 3 trial of REGEN-COV in non-hospitalised patients with COVID-19 as per the recommendations from the Independent Data Monitoring Committee or IDMC. According to the company, the IDMC found... Moderna Inc. (MRNA) Thursday reported a fourth-quarter net loss that widened from last year. But quarterly revenues surged from the previous year, driven by increases in grant revenue and product sales. The company raised its 2021 COVID-19 vaccine manufacturing plan.
RELATED NEWS
Follow RTT